| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Silence Therapeutics Plc
13D/A
Amendment 11
G8128Y157
|
8.0% |
8/13/2026
Event 8/12/2026
|
|||
|
Silence Therapeutics Plc
13D/A
Amendment 10
G8128Y157
|
21.7% |
7/8/2026
Event 7/6/2026
|
|||
| Richard Griffiths | 21.7% | ||||
| Ora Capital Limited | 13.5% | ||||
|
Silence Therapeutics Plc
13D/A
Amendment 9
G8128Y157
|
24.4% |
6/25/2025
Event 6/25/2025
|
|||
| Richard Ian Griffiths | 24.4% | ||||
| Ora Capital Limited | 13.6% | ||||
|
Silence Therapeutics Plc
13D/A
Amendment 8
G8128Y157
|
23.2% |
5/8/2025
Event 5/7/2025
|
|||
| Richard Ian Griffiths | 23.2% | ||||
| Ora Capital Limited | 13.6% | ||||
|
Silence Therapeutics Plc
13D/A
Amendment 7
G8128Y157
|
21.8% |
4/24/2025
Event 4/24/2025
|
|||
| Richard Ian Griffiths | 21.8% | ||||
| Ora Capital Limited | 13.6% | ||||
|
Silence Therapeutics Plc
13D/A
Amendment 6
G8128Y157
|
20.7% |
3/31/2025
Event 3/31/2025
|
|||
| Richard Ian Griffiths | 20.7% | ||||
| Ora Capital Limited | 13.6% | ||||
|
Silence Therapeutics Plc
13D/A
Amendment 5
G8128Y157
|
19.3% |
12/20/2024
Event 12/18/2024
|
|||
| Richard Ian Griffiths | 19.3% | ||||
| Ora Capital Limited | 13.6% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.